LinkGevity
LinkGevity develops drugs to extend healthspan by identifying and targeting biological triggers of aging. The company uses a proprietary AI-powered drug discovery platform and semantic processing to build 'Blueprint Maps' from large biomedical datasets, a framework it calls the Blueprint Theory. Its lead program, Anti-Necrotics™, comprises necrosis inhibitors being developed for acute kidney injury and applications in tissue engineering and organ preservation. LinkGevity operates as a drug discovery, licensing, and development partner for pharmaceutical and biotechnology companies focused on aging and age-related diseases.
LinkGevity
LinkGevity develops drugs to extend healthspan by identifying and targeting biological triggers of aging. The company uses a proprietary AI-powered drug discovery platform and semantic processing to build 'Blueprint Maps' from large biomedical datasets, a framework it calls the Blueprint Theory. Its lead program, Anti-Necrotics™, comprises necrosis inhibitors being developed for acute kidney injury and applications in tissue engineering and organ preservation. LinkGevity operates as a drug discovery, licensing, and development partner for pharmaceutical and biotechnology companies focused on aging and age-related diseases.